GlassScriptPhysician profile
Lisa M Oneil
NPI 1437252749
$4,065.68
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $709 · 2021: $983 · 2022: $753 · 2023: $810 · 2024: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $724.41 | 2019-2024 | Jardiance, Glyxambi, Spiriva Respimat |
| Glaxosmithkline, LLC. | $638.06 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $459.64 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $453.58 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $432.83 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $348.58 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $254.84 | 2019-2022 | |
| Pfizer INC. | $205.69 | 2019-2023 | |
| Novo Nordisk INC | $112.20 | 2020-2024 | Ozempic, Rybelsus |
| Dexcom, INC. | $99.14 | 2021-2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $87.05 | 2019-2020 | |
| Exact Sciences Corporation | $47.99 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $41.54 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.85 | 2021 | |
| Sanofi-Aventis U.S. LLC | $34.70 | 2019-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $32.41 | 2021 | |
| Astellas Pharma US INC | $22.58 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $17.06 | 2022 | |
| Ibsa Pharma INC. | $15.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Oneil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.